Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea-Reference-Cited by-同舟云学术

Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea

Published:2016-07-25 Issue:1 Volume:58 Page:89-95
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Douglas Genevieve,Harrison Claire,Forsyth Cecily,Bennett Michael,Stevenson William,Hounsell John,Ratnasingam Sumita,Ritchie David,Ross David M.,Grigg Andrew

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.1080/10428194.2016.1187269

Reference32 articles.

1. Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

2. Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN

3. Cyclical thrombocytosis, acquired von Willebrand syndrome and aggressive non-melanoma skin cancers are common in patients with Philadelphia-negative myeloproliferative neoplasms treated with hydroxyurea

4. Hydroxyurea induced oscillations in twelve patients with polycythemia vera

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. What are the future prospects for polycythemia vera pharmacotherapies for patients with hydroxyurea resistance?;Expert Opinion on Pharmacotherapy;2024-08-12

2. Moving toward disease modification in polycythemia vera;Blood;2023-11-30

3. Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and management;American Journal of Hematology;2023-06-26

4. An atypical oral presentation of polycythemia vera;Journal of Dentistry Defence Section;2023

5. Essential thrombocythemia: challenges in clinical practice and future prospects;Blood;2022-11-15